Category: Opinion
Thyme Care – Transforming the Oncology Patient Experience Head-On
“It’s cancer.” These words are overwhelming for any patient to hear. The reality is that 40% of Americans will be diagnosed with cancer in their lifetime; unfortunately, this means there is a high likelihood that…
In Memoriam – Stephen Kaldor
It is with heavy hearts that we reflect back on our time working with one of this generation’s best drug hunters, Stephen Kaldor. Steve passed away on August 8, 2022 in San Diego. He was…
New Hope for Cancer Patients with No Other Treatment Options
Today we are pleased to announce Foresite Capital’s investment in ImmPACT Bio, which we co-led with Venbio and Decheng Capital. We’re excited about ImmPACT’s focus on next generation cancer therapies based on transformative chimeric antigen receptor (CAR) T-cell therapies for…
Introducing the Tananbaum Center for Theoretical and Analytical Human Biology at Yale University
It’s an exciting time to be in the life sciences, with advances in multiple scientific fields coming together to further our understanding of human health and disease. A key part of our investment focus at Foresite…
Announcing Fund V
Today is an important day in the history of Foresite Capital, the firm I founded in 2011: we announced our largest fundraise to date, $969 million in Fund V and its accompanying Opportunity Fund. We…
Reflecting on Kinnate Biopharma
Today is an important day for Foresite Capital and our portfolio company, Kinnate Biopharma. Kinnate began trading today on the NASDAQ (KNTE). I’d like to take a moment to reflect on the incredibly fast journey…
